Defining resistance mechanisms to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer
- 9 October 2020
- journal article
- editorial
- Published by Elsevier BV in Annals of Oncology
- Vol. 31 (12), 1599-1600
- https://doi.org/10.1016/j.annonc.2020.10.002
Abstract
No abstract availableFunding Information
- Novartis
- Merck Sharp and Dohme
- Bristol-Myers Squibb
- AstraZeneca
- National Health and Medical Research Council
This publication has 19 references indexed in Scilit:
- Selective RET kinase inhibition for patients with RET-altered cancersAnnals of Oncology, 2018
- Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET RegistryJournal of Clinical Oncology, 2017
- RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 PatientsClinical Cancer Research, 2017
- Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trialThe Lancet Respiratory Medicine, 2016
- Cabozantinib in patients with advanced RET -rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trialThe Lancet Oncology, 2016
- Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trialAnnals of Oncology, 2016
- A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinomaNature Reviews Endocrinology, 2016
- The landscape of kinase fusions in cancerNature Communications, 2014
- Cabozantinib in Progressive Medullary Thyroid CancerJournal of Clinical Oncology, 2013
- Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III TrialJournal of Clinical Oncology, 2012